Emerging drugs for primary progressive multiple sclerosis

References

• McFarland HF, Martin R. Multiple sclerosis: a complicated picture of autoimmunity. Nat Immunol. 2007;8:913–919.
   PubMed Web of Science ®Google Scholar
• Trapp BD, Nave K-A. Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci. 2008;31:247–269.
   PubMed Web of Science ®Google Scholar
• Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83:278–286.
   PubMed Web of Science ®Google Scholar
• Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) advisory committee on clinical trials of new agents in multiple sclerosis. Neurology. 1996;46:907–911.
   PubMed Web of Science ®Google Scholar
• Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol. 2005 Dec;58::840–846.
   PubMed Web of Science ®Google Scholar
• Thompson AJ. Challenge of progressive multiple sclerosis therapy. Curr Opin Neurol. 2017;30:237–240.
   PubMed Web of Science ®Google Scholar
• Ontaneda D, Fox RJ, Chataway J. Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives. Lancet Neurol. 2015;14(2):208–223.
   PubMed Web of Science ®Google Scholar
• Malmeström C, Haghighi S, Rosengren L, et al. Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS. Neurology. 2003;61:1720–1725.
   PubMed Web of Science ®Google Scholar
• Pender MP, Csurhes PA, Wolfe NP, et al. Increased circulating T cell reactivity to GM3 and GQ1b gangliosides in primary progressive multiple sclerosis. J Clin Neurosci. 2003;10:63–66.
   PubMed Web of Science ®Google Scholar
• Huang Q, Xiao B, Ma X, et al. MicroRNAs associated with the pathogenesis of multiple sclerosis. J Neuroimmunol. 2016;295-296:148–161.
   PubMed Web of Science ®Google Scholar
• Racke MK. Experimental autoimmune encephalomyelitis (EAE). Curr Protoc Neurosci 2001. May; Chapter 9: Unit 9.7
   PubMedGoogle Scholar
• Robinson AP, Harp CT, Noronha A, et al. The experimental autoimmune encephalomyelitis (EAE) model of MS: utility for understanding disease pathophysiology and treatment. Handb Clin Neurol. 2014;122:173–189.
   PubMedGoogle Scholar
• Levy H, Assaf Y, Frenkel D. Characterization of brain lesions in a mouse model of progressive multiple sclerosis. Exp Neurol. 2010;226:148–158.
   PubMed Web of Science ®Google Scholar
• International Multiple Sclerosis Genetics. Network-based multiple sclerosis pathway analysis with GWAS data from 15,000 cases and 30,000 controls. Am J Hum Genet. 2013;92:854–865.
   PubMed Web of Science ®Google Scholar
• Browne P, Chandraratna D, Angood C, et al. Atlas of Multiple Sclerosis 2013: a growing global problem with widespread inequity. Neurology. 2014;83:1022–1024.
   PubMed Web of Science ®Google Scholar
• Whetten-Goldstein K, Sloan FA, Goldstein LB, et al. A comprehensive assessment of the cost of multiple sclerosis in the United States. Mult Scler. 1998;4:419–425.
   PubMed Web of Science ®Google Scholar
• Grima DT, Torrance GW, Francis G, et al. Cost and health related quality of life consequences of multiple sclerosis. Mult Scler. 2000;6:91–98.
   PubMed Web of Science ®Google Scholar
• Patwardhan MB, Matchar DB, Samsa GP, et al. Cost of multiple sclerosis by level of disability: a review of literature. Mult Scler. 2005;11:232–239.
   PubMed Web of Science ®Google Scholar
• International Progressive MS Alliance. Facts and figures.
   Google Scholar
• Fox RJ, Thompson A, Baker D, et al. Setting a research agenda for progressive multiple sclerosis: the International Collaborative on Progressive MS. Mult Scler. 2012;18:1534–1540.
   PubMed Web of Science ®Google Scholar
• Lucchinetti C, Brück W, Parisi J, et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol. 2000;47:707–717.
   PubMed Web of Science ®Google Scholar
• Barnett MH, Prineas JW. Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann Neurol. 2004;55:458–468.
   PubMed Web of Science ®Google Scholar
• Bjartmar C, Kidd G, Mörk S, et al. Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients. Ann Neurol. 2000;48:893–901.
   PubMed Web of Science ®Google Scholar
• Bjartmar C, Wujek JR, Trapp BD. Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease. J Neurol Sci. 2003;206:165–171.
   PubMed Web of Science ®Google Scholar
• Brownell B, Hughes JT. The distribution of plaques in the cerebrum in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1962;25:315–320.
   PubMed Web of Science ®Google Scholar
• Choi SR, Howell OW, Carassiti D, et al. Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis. Brain. 2012;135:2925–2937.
   PubMed Web of Science ®Google Scholar
• Howell OW, Reeves CA, Nicholas R, et al. Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. Brain. 2011;134:2755–2771.
   PubMed Web of Science ®Google Scholar
• Androdias G, Reynolds R, Chanal M, et al. Meningeal T cells associate with diffuse axonal loss in multiple sclerosis spinal cords. Ann Neurol. 2010;68:465–476.
   PubMed Web of Science ®Google Scholar
• Peterson JW, Bö L, Mörk S, et al. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol. 2001;50:389–400.
   PubMed Web of Science ®Google Scholar
• Wegner C, Esiri MM, Chance SA, et al. Neocortical neuronal, synaptic, and glial loss in multiple sclerosis. Neurology. 2006;67:960–967.
   PubMed Web of Science ®Google Scholar
• Kutzelnigg A, Faber-Rod JC, Bauer J, et al. Widespread demyelination in the cerebellar cortex in multiple sclerosis. Brain Pathol. 2007;17:38–44.
   PubMed Web of Science ®Google Scholar
• Geurts JJG, Bö L, Roosendaal SD, et al. Extensive hippocampal demyelination in multiple sclerosis. J Neuropathol Exp Neurol. 2007;66:819–827.
   PubMed Web of Science ®Google Scholar
• Vercellino M, Masera S, Lorenzatti M, et al. Demyelination, inflammation, and neurodegeneration in multiple sclerosis deep gray matter. J Neuropathol Exp Neurol. 2009;68:489–502.
   PubMed Web of Science ®Google Scholar
• Dutta R, Chang A, Doud MK, et al. Demyelination causes synaptic alterations in hippocampi from multiple sclerosis patients. Ann Neurol. 2011;69:445–454.
   PubMed Web of Science ®Google Scholar
• Kutzelnigg A, Lucchinetti CF, Stadelmann C, et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain. 2005;128:2705–2712.
   PubMed Web of Science ®Google Scholar
• De Stefano N, Matthews PM, Filippi M, et al. Evidence of early cortical atrophy in MS: relevance to white matter changes and disability. Neurology. 2003;60:1157–1162.
   PubMed Web of Science ®Google Scholar
• Franklin RJM, Ffrench-Constant C. Remyelination in the CNS: from biology to therapy. Nat Rev Neurosci. 2008;9:839–855.
   PubMed Web of Science ®Google Scholar
• Patrikios P, Stadelmann C, Kutzelnigg A, et al. Remyelination is extensive in a subset of multiple sclerosis patients. Brain. 2006;129:3165–3172.
   PubMed Web of Science ®Google Scholar
• Albert M, Antel J, Brück W, et al. Extensive cortical remyelination in patients with chronic multiple sclerosis. Brain Pathol. 2007;17:129–138.
   PubMed Web of Science ®Google Scholar
• Bramow S, Frischer JM, Lassmann H, et al. Demyelination versus remyelination in progressive multiple sclerosis. Brain. 2010;133:2983–2998.
   PubMed Web of Science ®Google Scholar
• Fischer MT, Sharma R, Lim JL, et al. NADPH oxidase expression in active multiple sclerosis lesions in relation to oxidative tissue damage and mitochondrial injury. Brain. 2012;135:886–899.
   PubMed Web of Science ®Google Scholar
• Gray E, Thomas TL, Betmouni S, et al. Elevated myeloperoxidase activity in white matter in multiple sclerosis. Neurosci Lett. 2008;444:195–198.
   PubMed Web of Science ®Google Scholar
• Mahad DJ, Ziabreva I, Campbell G, et al. Mitochondrial changes within axons in multiple sclerosis. Brain. 2009;132:1161–1174.
   PubMed Web of Science ®Google Scholar
• Kiryu-Seo S, Ohno N, Kidd GJ, et al. Demyelination increases axonal stationary mitochondrial size and the speed of axonal mitochondrial transport. J Neurosci. 2010;30:6658–6666.
   PubMed Web of Science ®Google Scholar
• Dutta R, McDonough J, Yin X, et al. Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Ann Neurol. 2006;59:478–489.
   PubMed Web of Science ®Google Scholar
• Murphy MP. How mitochondria produce reactive oxygen species. Biochem J. 2009;417:1–13.
   PubMed Web of Science ®Google Scholar
• Bagnato F, Hametner S, Yao B, et al. Tracking iron in multiple sclerosis: a combined imaging and histopathological study at 7 Tesla. Brain. 2011;134:3602–3615.
   PubMed Web of Science ®Google Scholar
• Mehta V, Pei W, Yang G, et al. Iron is a sensitive biomarker for inflammation in multiple sclerosis lesions. PLoS One. 2013;8:e57573.
   PubMed Web of Science ®Google Scholar
• Berio A, Di Stefano A, Bellati R, et al. Fecal elimination of amines in normal and pathological conditions. Minerva Pediatr. 1971;23:660–667.
   PubMedGoogle Scholar
• Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33:1444–1452.
   PubMed Web of Science ®Google Scholar
• Pöhlau D, Przuntek H, Sailer M, et al. Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study. Mult Scler. 2007;13:1107–1117.
   PubMed Web of Science ®Google Scholar
• Wolinsky JS, P.R.T.S. Group. The PROMiSe trial: baseline data review and progress report. Mult Scler 2004;10(Suppl 1):S65–S71. ( discussion S71-2).
   PubMedGoogle Scholar
• Wolinsky JS, Narayana PA, O’Connor P, et al. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol. 2007;61:14–24.
   PubMed Web of Science ®Google Scholar
• Wolinsky JS, Shochat T, Weiss S, et al. Glatiramer acetate treatment in PPMS: why males appear to respond favorably. J Neurol Sci. 2009;286:92–98.
   PubMed Web of Science ®Google Scholar
• Grey Née Cotte S, Salmen Née Stroet A, Von Ahsen N, et al. Lack of efficacy of mitoxantrone in primary progressive multiple sclerosis irrespective of pharmacogenetic factors: a multi-center, retrospective analysis. J Neuroimmunol. 2015;278:277–279.
   PubMed Web of Science ®Google Scholar
• Rojas JI, et al. Interferon beta for primary progressive multiple sclerosis. Cochrane Database Syst Rev. 2010;Jan 20;(1):CD006643
   PubMed Web of Science ®Google Scholar
• Rojas J.I., et al. Interferon beta for primary progressive multiple sclerosis. Cochrane Database Syst Rev. 2009;Jan 21;(1):CD006643.
   Web of Science ®Google Scholar
• Lublin F, Miller DH, Freedman MS, et al. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2016;387:1075–1084.
   PubMed Web of Science ®Google Scholar
• Hawker K, O’Connor P, Freedman MS, et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol. 2009;66:460–471.
   PubMed Web of Science ®Google Scholar
• Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus placebo in primary progressive multiple aclerosis. N Engl J Med. 2017;376:209–220.
   PubMed Web of Science ®Google Scholar
• Absinta M, Vuolo L, Rao A, et al. Gadolinium-based MRI characterization of leptomeningeal inflammation in multiple sclerosis. Neurology. 2015;85:18–28.
   PubMed Web of Science ®Google Scholar
• Segal BM, Stüve O. Primary progressive multiple sclerosis – why we are failing. Lancet. 2016;387(10023):1032–1034.
   PubMed Web of Science ®Google Scholar
• Arnason BG, Berkovich R, Catania A, et al. Mechanisms of action of adrenocorticotropic hormone and other melanocortins relevant to the clinical management of patients with multiple sclerosis. Mult Scler. 2013;19:130–136.
   PubMed Web of Science ®Google Scholar
• Catania A. Neuroprotective actions of melanocortins: a therapeutic opportunity. Trends Neurosci. 2008;31:353–360.
   PubMed Web of Science ®Google Scholar
• Vergo S, Craner MJ, Etzensperger R, et al. Acid-sensing ion channel 1 is involved in both axonal injury and demyelination in multiple sclerosis and its animal model. Brain. 2011;134:571–584.
   PubMed Web of Science ®Google Scholar
• Friese MA, Craner MJ, Etzensperger R, et al. Acid-sensing ion channel-1 contributes to axonal degeneration in autoimmune inflammation of the central nervous system. Nat Med. 2007;13:1483–1489.
   PubMed Web of Science ®Google Scholar
• Arun T, Tomassini V, Sbardella E, et al. Targeting ASIC1 in primary progressive multiple sclerosis: evidence of neuroprotection with amiloride. Brain. 2013;136:106–115.
   PubMed Web of Science ®Google Scholar
• Said HM. Biotin: the forgotten vitamin. Am J Clin Nutr. 2002;75:179–180.
   PubMed Web of Science ®Google Scholar
• Sedel F. A novel biotin-sensitive leukodystrophy (BSL). Inherit Metab Dis. 2011; 34(Suppl 3):S267
   Web of Science ®Google Scholar
• Sedel F, Papeix C, Bellanger A, et al. High doses of biotin in chronic progressive multiple sclerosis: a pilot study. Mult Scler Relat Disord. 2015;4:159–169.
   PubMed Web of Science ®Google Scholar
• Tourbah A, Lebrun-Frenay C, Edan G, et al. MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: a randomised, double-blind, placebo-controlled study. Mult Scler. 2016;22:1719–1731.
   PubMed Web of Science ®Google Scholar
• Tourbah A. Effect of MD1003 (high doses of biotin) in chronic visual loss related to optic neuritis in multiple sclerosis (MS-ON): results of a pivotal randomized double masked placebo controlled study. 2016; 86 (16 Supplement)
   Google Scholar
• Plantone D, De Angelis F, et al. Dimethyl fumarate may still have a role in progressive multiple sclerosis. Ther Adv Neurol Disord. 2016;9:344–345.
   PubMed Web of Science ®Google Scholar
• Wang Q, Chuikov S, Taitano S, et al. Dimethyl fumarate protects neural stem/progenitor cells and neurons from oxidative damage through Nrf2-ERK1/2 MAPK Pathway. Int J Mol Sci. 2015;16:13885–13907.
   PubMed Web of Science ®Google Scholar
• Higashi C, Kawaji A, Tsuda N, et al. The novel Nrf2 inducer TFM-735 ameliorates experimental autoimmune encephalomyelitis in mice. Eur J Pharmacol. 2017;802:76–84.
   PubMed Web of Science ®Google Scholar
• Strassburger-Krogias K, Ellrichmann G, et al. Fumarate treatment in progressive forms of multiple sclerosis: first results of a single-center observational study. Ther Adv Neurol Disord. 2014;7:232–238.
   PubMed Web of Science ®Google Scholar
• Novakova L, Zetterberg H, Sundström P, et al. Monitoring disease activity in multiple sclerosis using serum neurofilament light protein. Neurology. 2017;89:2230–2237.
   PubMed Web of Science ®Google Scholar
• Gnanapavan S, Grant D, Morant S, et al., Biomarker report from the phase II lamotrigine trial in secondary progressive MS – neurofilament as a surrogate of disease progression. PLoS One, 2013. 8: e70019
   PubMed Web of Science ®Google Scholar
• Brines M, et al. Emerging Biological Roles for Erythropoietin in the Nervous System. Nat Rev Neurosci. 2005;6:484–494.
   PubMed Web of Science ®Google Scholar
• Bartels C, Späte K, Krampe H, et al. Recombinant human erythropoietin: novel strategies for neuroprotective/neuro-regenerative treatment of multiple sclerosis. Ther Adv Neurol Disord. 2008;1:193–206.
   PubMedGoogle Scholar
• Ehrenreich H, Fischer B, Norra C, et al. Exploring recombinant human erythropoietin in chronic progressive multiple sclerosis. Brain. 2007;130:2577–2588.
   PubMed Web of Science ®Google Scholar
• Zhang F, Zhou H, Wilson BC, et al. Fluoxetine protects neurons against microglial activation-mediated neurotoxicity. Parkinsonism Relat Disord. 2012;18(Suppl 1):S213–S217.
   PubMedGoogle Scholar
• Alme MN, Wibrand K, Dagestad G, et al. Chronic fluoxetine treatment induces brain region-specific upregulation of genes associated with BDNF-induced long-term potentiation. Neural Plast. 2007;2007:26496.
   PubMedGoogle Scholar
• Mostert JP, Sijens PE, Oudkerk M, et al. Fluoxetine increases cerebral white matter NAA/Cr ratio in patients with multiple sclerosis. Neurosci Lett. 2006;402:22–24.
   PubMed Web of Science ®Google Scholar
• Koch MW, Zabad R, Giuliani F, et al. Hydroxychloroquine reduces microglial activity and attenuates experimental autoimmune encephalomyelitis. J Neurol Sci. 2015;358:131–137.
   PubMed Web of Science ®Google Scholar
• Feng J, Misu T, Fujihara K, et al. Ibudilast, a nonselective phosphodiesterase inhibitor, regulates Th1/Th2 balance and NKT cell subset in multiple sclerosis. Mult Scler. 2004;10:494–498.
   PubMed Web of Science ®Google Scholar
• Fox RJ, Coffey C, et al. SPRINT-MS/NN 102 phase II trial of ibudilast in progressive MS: baseline characteristics. ECTRIMS Online Library. Fox R Oct. 2015;9:115134.
   Google Scholar
• Jaber S, Polster BM, et al. Idebenone and neuroprotection: antioxidant, pro-oxidant, or electron carrier?. J Bioenerg Biomembr. 2015;47(p):111–118.
   PubMedGoogle Scholar
• Thöne J, Linker RA, et al. Laquinimod in the treatment of multiple sclerosis: a review of the data so far. Drug Des Devel Ther. 2016; 10: 1111–18.
   PubMed Web of Science ®Google Scholar
• Jolivel V, Luessi F, Masri J, et al. Modulation of dendritic cell properties by laquinimod as a mechanism for modulating multiple sclerosis. Brain. 2013;1048–1066.
   PubMed Web of Science ®Google Scholar
• Thöne J, Ellrichmann G, Seubert S, et al. Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor. Am J Pathol. 2012;180:267–274.
   PubMed Web of Science ®Google Scholar
• Mishra MK, Wang J, Keough MB, et al. Laquinimod reduces neuroaxonal injury through inhibiting microglial activation. Clin Transl Neurol. 2014;1:409–422.
   PubMed Web of Science ®Google Scholar
• Dugas JC, Ibrahim A, Barres BA. The T3-induced gene KLF9 regulates oligodendrocyte differentiation and myelin regeneration. Mol Cell Neurosci. 2012;50:45–57.
   PubMed Web of Science ®Google Scholar
• EL-Tahry H, Marei H, Shams A, et al. The effect of triiodothyronine on maturation and differentiation of oligodendrocyte progenitor cells during remyelination following demyelination in male albino rat. Tissue Cell. 2016;48:242–251.
   PubMed Web of Science ®Google Scholar
• Zendedel A, Kashani IR, Azimzadeh M, et al. Regulatory effect of triiodothyronine on brain myelination and astrogliosis after cuprizone-induced demyleination in mice. Metab Brain Dis. 2016;31:425–433.
   PubMed Web of Science ®Google Scholar
• Wirth EK, Meyer F. Neuronal effects of thyroid hormone metabolites. Mol Cell Endocrinol. 2017;458:136–142.
   PubMed Web of Science ®Google Scholar
• Salinthone S, Yadav V, Bourdette DN, et al. Lipoic acid: a novel therapeutic approach for multiple sclerosis and other chronic inflammatory diseases of the CNS. Endocr Metab Immune Disord Drug Targets. 2008;8:132–142.
   PubMedGoogle Scholar
• Marracci GH, Jones RE, McKeon GP, et al. Alpha lipoic acid inhibits T cell migration into the spinal cord and suppresses and treats experimental autoimmune encephalomyelitis. J Neuroimmunol. 2002;131(1-2):104-14.
   PubMedGoogle Scholar
• Yadav V, Marracci G, Lovera J, et al. Lipoic acid in multiple sclerosis: a pilot study. Mult Scler. 2005;11:159–165.
   PubMed Web of Science ®Google Scholar
• Rowse AL., et al. Lithium controls central nervous system autoimmunity through modulation of IFN-gamma signaling. PLoS One. 2012;7:e52658.
   PubMed Web of Science ®Google Scholar
• De Sarno P, Axtell RC, Raman C, et al. Lithium prevents and ameliorates experimental autoimmune encephalomyelitis. J Immunol. 2008;181:338–345.
   PubMed Web of Science ®Google Scholar
• Levine S, Saltzman A. Inhibition of experimental allergic encephalomyelitis by lithium chloride: specific effect or nonspecific stress? Immunopharmacology. 1991;22:207–213.
   PubMedGoogle Scholar
• Dubreuil P, Letard S, Ciufolini M, et al. Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT. PLoS One. 2009;4:e7258.
   PubMed Web of Science ®Google Scholar
• Theoharides TC, Kempuraj D, Kourelis T, et al. Human mast cells stimulate activated T cells: implications for multiple sclerosis. Ann N Y Acad Sci. 2008;1144:74–82.
   PubMed Web of Science ®Google Scholar
• Vermersch P, Benrabah R, Schmidt N, et al. Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study. BMC Neurol. 2012;12:36.
   PubMed Web of Science ®Google Scholar
• Romme Christensen J, Ratzer R, Börnsen L, et al. Natalizumab in progressive MS: results of an open-label, phase 2A, proof-of-concept trial. Neurology. 2014;82:1499–1507.
   PubMed Web of Science ®Google Scholar
• Cheah BC, Vucic S, Krishnan AV, et al. Riluzole, neuroprotection and amyotrophic lateral sclerosis. Curr Med Chem. 2010;17:1942–1959.
   PubMed Web of Science ®Google Scholar
• Kalkers NF, Barkhof F, Bergers E, et al. The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot study. Mult Scler. 2002;8:532–533.
   PubMed Web of Science ®Google Scholar
• Magliozzi R, Howell O, Vora A, et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain. 2007;130:1089–1104.
   PubMed Web of Science ®Google Scholar
• Bonnan M, Ferrari S, Bertandeau E, et al. Intrathecal rituximab therapy in multiple sclerosis: review of evidence supporting the need for future trials. Curr Drug Targets. 2014;15:1205–1214.
   PubMed Web of Science ®Google Scholar
• Komori M, Lin YC, Cortese I, et al. Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis. Ann Clin Transl Neurol. 2016;3(3):166–179.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Cabrera, P.J., et al. S1P signaling: new therapies and opportunities. F1000Prime Rep. 2014;6:109.
   PubMedGoogle Scholar
• Novgorodov AS, El-Alwani M, Bielawski J, et al. Activation of sphingosine-1-phosphate receptor S1P5 inhibits oligodendrocyte progenitor migration. Faseb J. 2007;21:1503–1514.
   PubMed Web of Science ®Google Scholar
• Brana C, Frossard MJ, Pescini Gobert R, et al. Immunohistochemical detection of sphingosine-1-phosphate receptor 1 and 5 in human multiple sclerosis lesions. Neuropathol Appl Neurobiol. 2014;40:564–578.
   PubMed Web of Science ®Google Scholar
• Soliven B, Miron V, Chun J. The neurobiology of sphingosine 1-phosphate signaling and sphingosine 1-phosphate receptor modulators. Neurology. 2011;76:S9–S14.
   PubMed Web of Science ®Google Scholar
• Kappos L, Li DKB, Stüve O, et al. Safety and efficacy of siponimod (BAF312) in patients with relapsing-remitting multiple sclerosis: dose-blinded, randomized extension of the phase 2 BOLD study. JAMA Neurol. 2016;73:1089–1098.
   PubMed Web of Science ®Google Scholar
• Selmaj K, Li DKB, Hartung H-P, et al. Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. Lancet Neurol. 2013;12:756–767.
   PubMed Web of Science ®Google Scholar
• Aktas O, Prozorovski T, Smorodchenko A, et al. Green tea epigallocatechin-3-gallate mediates T cellular NF-kappa B inhibition and exerts neuroprotection in autoimmune encephalomyelitis. J Immunol. 2004;173:5794–5800.
   PubMed Web of Science ®Google Scholar
• Sun Q, Zheng Y, Zhang X, et al. Novel immunoregulatory properties of EGCG on reducing inflammation in EAE. Front Biosci (Landmark Ed). 2013;18:332–342.
   PubMed Web of Science ®Google Scholar
• Harrison DM, Roy S, Oh J, et al. Association of cortical lesion burden on 7-T magnetic resonance imaging with cognition and disability in multiple sclerosis. JAMA Neurology. 2015;72:1004–1012.
   PubMed Web of Science ®Google Scholar
• Komori M, Blake A, Greenwood M, et al. Cerebrospinal fluid markers reveal intrathecal inflammation in progressive multiple sclerosis. Ann Neurol. 2015;78:3–20.
   PubMed Web of Science ®Google Scholar
• Moccia M, De Stefano N, Barkhof F. Imaging outcome measures for progressive multiple sclerosis trials. Mult Scler. 2017;23:1614–1626.
   PubMedGoogle Scholar